Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Date:5/9/2011

ays on hand of Testim inventory by approximately seven days.  The Company has estimated this shortfall in sales during the quarter to be approximately $3.5 million in net revenues.
  • Total prescriptions within the gel segment of the testosterone replacement therapy market in the U.S. increased 13% versus the first quarter of 2010, according to IMS.
  • Testim ended the month of March with a 21.4% share of total prescriptions for testosterone gels in the U.S., compared to 22.2% at the end of March 2010, according to IMS.  

  • Updated Guidance:

  • As a result of the $30 million in regulatory milestones received from Pfizer and the $15 million in milestones received from Asahi Kasei Pharma, the Company is increasing full year 2011 XIAFLEX contract and ex-U.S. revenues from the previously stated guidance of a range of $5 to $7 million to a range of $9 to $11 million.
  • The increase in XIAFLEX contract and ex-U.S. revenues changes full year 2011 net loss guidance from the previously stated guidance of a range of $(35) to $(45) million to a range of $(31) to $(41) million for the year.

  • Global Testim Revenues

    $200 - 210 millionXIAFLEX:U.S. Revenues

    50 - 60 millionEx U.S. / Def Rev

    9 - 11 millionTotal XIAFLEX

    $59 - 71 millionTotal Revenues

    $259 -281 millionR & D Expense

    $60 - 70 millionS G & A Expense

    $170 - 180 millionNet Income (Loss)

    $(31) - (41) millionStock Base Comp Expense

    $15 - 20 millionFirst Quarter 2011 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars): Quarter EndQuarter EndIncrease3/31/20113/31/2010 (Decrease)Testim U.S. Revenue

    $45.5$43.94%Testim Ex – U.S. & Contract Revenue

    0.60.388%Total Testim Revenue

    $46.1$44.24%XIAFLEX U.S. Revenue

    $8.7$0.25083%XIAFLEX Revenue Recognition Change

    1.80.0n/aXIAFLEX Contract Revenue

    1.81.164%
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
    3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
    4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
    6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
    7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
    8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
    9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
    10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
    11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)...  MiMedx Group, Inc. (NASDAQ: MDXG ... patent protected regenerative biomaterials and bioimplants processed from ... peer-reviewed clinical study.    The study ... Clinical Trial Evaluating the Use of ... Compression Therapy vs. Multi-layer Compression Therapy Alone in ...
    (Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
    (Date:9/17/2014)... 17, 2014 Intarcia Therapeutics, Inc. ... a study of the cost and predictability of non-adherence ... Annual Meeting of the European Association for the ... Christian Frois , Ph.D., of Analysis Group, Inc. ... planned Intarcia-sponsored, retrospective studies to characterize the prevalence of ...
    (Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
    Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
    ... Sept. 4, 2007 Computing researchers at Houston,s ... Technological University (NTU) today announced the formation of ... joint research initiative, valued at 4 million Singapore ... costs for embedded microchips -- special-purpose computer chips ...
    ... WARSAW, Ind., Sept. 4 ,Tutogen Medical, Inc. (Amex: ... implant products made from human (allograft) and animal,(xenograft) ... ZMH), a leader,in the orthopaedics industry, today announced ... a wholly owned subsidiary of Zimmer,Holdings, Inc., into ...
    ... 4 Telik, Inc.,(Nasdaq: TELK ) announced that ... Annual Bear Stearns Healthcare Conference in New York,City on ... (8:30 a.m.,Pacific time). Telik,s presentation will be webcast live ... http://www.telik.com, ,through September 18, 2007. Telik, Inc. ...
    Cached Biology Technology:Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 2Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 3Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 4Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 5
    (Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
    (Date:9/18/2014)... September 18, 2014 Elsevier, a world-leading provider ... services, and the Australasian Research Management Society (ARMS), ... scientists at the 5th Scopus Young Researcher of ... earlier today at the National Convention Centre and ... was attended by guests representing Australia,s and New ...
    (Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
    Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2
    ... adults with the blood cancer mixed-lineage leukemia (MLL) typically have ... birthdays. Although there are varying causes of MLL, most cases ... and the AF4 genes. When the ... cancer-causing oncogene is created. Although researchers have known that the ...
    ... engineering holds great promise for the treatment of conditions ... injuries. However, bone and cartilage currently produced in ... the body so they,re not clinically viable. Dr. ... of Medicine & Dentistry at The University of Western ...
    ... 2008 -- A rat thought extinct for 11 million years ... new species discovered in the Greater Mekong Region of Southeast ... launched by World Wildlife Fund (WWF). First ... discovered or newly identified by science between 1997 and 2007 ...
    Cached Biology News:Tracking the molecular pathway to mixed-lineage leukemia 2Building better bones and tissue in the lab 2Over 1,000 species discovered in the Greater Mekong in past decade 2
    14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
    Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
    Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
    Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
    Biology Products: